Effectiveness of Oral Semaglutide in Management of Type 2 Diabetes: A Real-World Study from India

Effectiveness of Oral Semaglutide in Management of Type 2 Diabetes: A Real-World Study from India

Introduction: Oral Semaglutide (Sema-o) is the first oral glucagon like peptide-1 receptor analogue (GLP-1RA) commercially available for the treatment of type 2 diabetes (T2D). This study aimed to evaluate the efficacy of Sema-o in patients with T2D when added to the existing therapy. Methods: This...

Full description

Saved in:

Bibliographic Details
Main Authors:	Aditya Dutta, Shama Mahendru, Rutuja Sharma, Ambrish Mithal
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2024-12-01
Series:	Indian Journal of Endocrinology and Metabolism
Subjects:	hba1c oral semaglutide type 2 diabetes weight loss
Online Access:	https://journals.lww.com/10.4103/ijem.ijem_266_24
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Real-World Effectiveness of Oral Semaglutide in Indian Adult Diabetic Patients: Evaluation of EMR-based Data
by: Sandeep Gudibanda, et al.
Published: (2024-10-01)

Effectiveness and Side Effect Incidence in a Real-World Digital Weight-Loss Service Using Compounded Semaglutide: A Retrospective Comparative Study
by: Louis Talay, et al.
Published: (2024-10-01)

Real-world effectiveness of Semaglutide treatment on weight loss maintenance after weight loss in patients with obesity or overweight and diabetes
by: Michela Del Prete, et al.
Published: (2025-01-01)

Race of GLPS: Impact on Weight and Glycemic Control on Type 2 Diabetes with Semaglutide Versus Liraglutide
by: Noha Hafeez, et al.
Published: (2024-12-01)

Made in China: The international supply of illicit Semaglutide and weight-loss medicines online
by: Luke A. Turnock, et al.
Published: (2025-12-01)

The Effects of Oral Semaglutide on Hepatic Fibrosis in Subjects with Type 2 Diabetes in Real-World Clinical Practice: A Post Hoc Analysis of the Sapporo-Oral SEMA Study
by: Hiroya Kitsunai, et al.
Published: (2025-01-01)

Insights into the Efficacy of GLP-1 Agonists and Dual Agonists: Semaglutide and Tirzepatide in Obesity and Type 2 Diabetes
by: Laura Opalska, et al.
Published: (2024-12-01)

Reversible bilateral central scotoma under scotopic conditions associated with oral semaglutide
by: Peter Bracha, et al.
Published: (2024-12-01)

Spotlight on the Mechanism of Action of Semaglutide
by: Ilias Papakonstantinou, et al.
Published: (2024-12-01)

Semaglutide, type 2 diabetes, and the risk of nonarteritic anterior ischemic optic neuropathy
by: Fernando K. Malerbi, et al.
Published: (2025-01-01)

Oral Candidiasis in Diabetes Patients
by: Mustafa Naeem
Published: (2024-12-01)

Management of obesity with semaglutide or metformin in patients with antipsychotic-induced weight gain (MOSA): a non-randomised open-label pilot study
by: Bea Campforts, et al.
Published: (2024-11-01)

Semaglutide Reduces Cardiomyocyte Damage Caused by High-Fat Through HSDL2
by: Yang L, et al.
Published: (2024-11-01)

Comparison of GLP-1RAs vs Other Pharmacotherapy for Obesity
by: Andrew Overholser, et al.
Published: (2025-02-01)

Semaglutide, liraglutide and tirzepatide: Comparison of effectiveness in the treatment of obesity – a literature review
by: Karolina Baran, et al.
Published: (2024-12-01)

Diabetes Mellitus and Periodontitis: Relevance of the Diabolic Duo in India
by: Sumidha Bansal, et al.
Published: (2020-01-01)

Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial
by: Jelena Petković-Dabić, et al.
Published: (2025-01-01)

Glucagon-like peptide 1 receptor agonists in obesity treatment - a literature review
by: Aleksander Jentkiewicz, et al.
Published: (2025-02-01)

Predicting responsiveness to GLP-1 pathway drugs using real-world data
by: Xiaodong Zhu, et al.
Published: (2024-12-01)

Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis
by: Deep Dutta, et al.
Published: (2024-11-01)

Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes
by: Jakob Grauslund, et al.
Published: (2024-12-01)

Physician Perceptions of the Safety and Efficacy of GLP-1 Receptor Agonists: Underestimation of Cardiovascular Risk Reduction and Discrepancies with Clinical Evidence
by: Srikanth Krishnan, et al.
Published: (2025-01-01)

Efficacy and safety of once-weekly semaglutide monotherapy in a young subject with Prader-Willi syndrome, obesity, and type 2 diabetes: a case report
by: Elisa Dinoi, et al.
Published: (2025-02-01)

Cardiometabolic Modulation by Semaglutide Contributes to Cardioprotection in Rats with Myocardial Infarction
by: Yan H, et al.
Published: (2024-11-01)

The Influence of GLP1 on Body Weight and Glycemic Management in Patients with Diabetes—A Scientometric Investigation and Visualization Study
by: Ileana Pantea, et al.
Published: (2024-10-01)

Case report: Long-term efficacy and safety of semaglutide in the treatment of syndromic obesity in Prader Willi syndrome - case series and literature review
by: Andrijana Koceva, et al.
Published: (2025-01-01)

A patient choice‐driven lifestyle intervention lowers HbA1c in type 2 diabetes: A feasibility study
by: Nathan R. Weeldreyer, et al.
Published: (2025-01-01)

Creatine Phosphokinase Level Accompanied with Macro-Creatine Phosphokinase Type 1 Negatively Correlates with Plasma Glucose Control in a Patient with Type 2 Diabetes Mellitus
by: Koji Kikkawa, et al.
Published: (2022-05-01)

Exploring the Impact of Semaglutide on Cognitive Function and Anxiety-Related Behaviors in a Murine Model of Alzheimer’s Disease
by: Ianis Kevyn Stefan Boboc, et al.
Published: (2024-11-01)

Factors Influencing Glycemic Control in Children with Type 1 Diabetes
by: Seher Çakır, et al.
Published: (2010-05-01)

EFFECTIVENESS OF WALKING EXERCISE ON HBA1C AND BMI OF DIABETES MELLITUS TYPE 2: A SYSTEMATIC REVIEW
by: Nurul Fitri, et al.
Published: (2024-12-01)

Impact of Fasting on Physical Activity Motivation and Weight Reduction in Patients Administered Glucagon-Like Peptide-1 Agonists: A Qualitative Study
by: Almaqhawi A, et al.
Published: (2025-01-01)

Investigating the potential role of T helper 17 cells among women experiencing overweight and obesity and their possible therapeutic targeting of the RORγt molecule
by: Renad M. Alhamawi, et al.
Published: (2024-11-01)

Metformin plus lifestyle interventions versus lifestyle interventions alone for the delay or prevention of type 2 diabetes in individuals with prediabetes: a meta-analysis of randomized controlled trials
by: Basma Ehab Amer, et al.
Published: (2024-11-01)

Serum levels of sclerostin in prediabetes and its correlation with bone mineral density
by: Ajay Chauhan, et al.
Published: (2023-11-01)

Effects of Melatonin on Some Antioxidant Enzymes in Streptozotocin-induced Diabetic Rats
by: Ercan Keskin, et al.
Published: (2019-09-01)

The Impact of Time-Restricted Eating and Intermittent Fasting on Glycemia, Body Weight, and Overall Well-Being in Patients with Type 2 Diabetes – A Review of Studies
by: Szymon Przemysław Stolarczyk, et al.
Published: (2025-02-01)

Exploring the Role of Vitamin D2, Parathyroid Hormone, and C-Peptides as Biomarkers in Diabetic Neuropathy Development
by: Ban Mahmood Shaker Al-Joda, et al.
Published: (2024-07-01)

Intermittent Use of Flash Glucose Monitoring Improves Glycemic Control in Chinese Older Patients with Type 2 Diabetes Mellitus
by: Hu Y, et al.
Published: (2025-01-01)

Correlation Between Serum Uric Acid, Insulin and Hba1c In Type 2 Diabetes Mellitus
by: Maryam Imtiaz, et al.
Published: (2024-06-01)